Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.

Yu Yagi,Yusuke Kanemasa,Yuki Sasaki, Mina Sei,Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino,An Ohigashi,Yuka Morita,Taichi Tamura,Shohei Nakamura,Toshihiro Okuya,Takuya Shimizuguchi,Naoki Shingai,Takashi Toya,Hiroaki Shimizu,Yuho Najima,Takeshi Kobayashi,Kyoko Haraguchi,Noriko Doki,Yoshiki Okuyama,Tatsu Shimoyama

Cancer medicine（2023）

引用 1|浏览9

暂无评分

摘要

In this study, we demonstrated that chemosensitivity remained a crucial factor in predicting survival outcomes following CAR T-cell therapy irrespective of the administration timing, and that both ASCT and CAR T-cell therapy were acceptable after the response to second-line salvage chemotherapy.

查看译文

关键词

autologous stem cell transplantation, chimeric antigen receptor T-cell therapy, relapsed or refractory diffuse large B-cell lymphoma, salvage chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要